Journal of neuroimmunology · 2022
Epileptic seizures in patients with anti-IgLON5 disease.
ОбзорКлинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Ying, Wang Yiqi, Zhao Xiaoyu, Zhang Sheng, Geng Yu, Zhang Zheyu, Jin Bo, Aung Thandar
Аннотация
BACKGROUND: Anti-IgLON5 is a rare neurologic disease that can present with epileptic seizures. However, epileptic seizures have not been characterized and are underreported. We aimed to investigate the clinical characteristics and demographics of epileptic seizures in patients with anti-IgLON5 disease.
METHODS: We reported a case of anti-IgLON5 disease presenting with epileptic seizures and presented a comprehensive literature review on epileptic seizures in patients with the anti-IgLON5 disease. We searched the Medline, Pubmed, and Web of Science databases using the following search algorithm: "IgLON5" or "anti-IgLON5" or "IgLON5 antibody" limited to publications in English.
RESULTS: We identified 183 cases from 66 publications. In addition to our case, nine (4.9%) patients with anti-IgLON5 disease had reported epileptic seizures, either focal or generalized. Of those, epileptic seizures were one of the main reasons for neurology consultation in six (3.2%). Patients with epileptic seizures affected both sexes similarly and usually developed in middle age. In addition to epileptic seizures, a majority of patients had sleep disorders and cognitive impairment. The frequency of epileptic seizures was reduced with the treatment of immunotherapy and antiseizure medication.
CONCLUSION: Anti-IgLON5 disease can present with epileptic seizures, and our study expands the clinical spectrum of the anti-IgLON5 disease.
METHODS: We reported a case of anti-IgLON5 disease presenting with epileptic seizures and presented a comprehensive literature review on epileptic seizures in patients with the anti-IgLON5 disease. We searched the Medline, Pubmed, and Web of Science databases using the following search algorithm: "IgLON5" or "anti-IgLON5" or "IgLON5 antibody" limited to publications in English.
RESULTS: We identified 183 cases from 66 publications. In addition to our case, nine (4.9%) patients with anti-IgLON5 disease had reported epileptic seizures, either focal or generalized. Of those, epileptic seizures were one of the main reasons for neurology consultation in six (3.2%). Patients with epileptic seizures affected both sexes similarly and usually developed in middle age. In addition to epileptic seizures, a majority of patients had sleep disorders and cognitive impairment. The frequency of epileptic seizures was reduced with the treatment of immunotherapy and antiseizure medication.
CONCLUSION: Anti-IgLON5 disease can present with epileptic seizures, and our study expands the clinical spectrum of the anti-IgLON5 disease.